A Phase 1 interventional study of Aramchol in NASH, sponsored by Galmed Pharmaceuticals Ltd. Completed at 1 site in United Kingdom. Open to male participants aged 35 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-24.
Sponsored by Galmed Pharmaceuticals Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A two-part open-label study to assess the absolute bioavailability of aramchol and the mass balance recovery, metabolite profile and identification of metabolite structures for [14C]-aramchol in healthy male subjects
A two-part open-label study to assess the absolute bioavailability of aramchol and the mass balance recovery, metabolite profile and identification of metabolite structures for [14C]-aramchol in healthy male subjects.
A subject was considered evaluable in Part 1 if they provided PK samples for up to a minimum of 120 h after first investigational medicinal product (IMP) administration. A subject was considered evaluable in Part 2 if they provided biological samples for up to a minimum of 144 h after IMP administration or demonstrated >90% mass balance recovery, or \<1% of the administered dose eliminated in excreta for 2 consecutive days, whichever was sooner.
Galmed Pharmaceuticals Ltd is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 subjects received Aramchol in Part 1 and Part 2 of the study
Drug: Aramchol
Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid) is a synthetic small molecule, produced by conjugation of cholic acid (bile acid) and arachidic acid (saturated fatty acid) linked by a stable amide bond.
Also known as: Aramchol free acid (3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid)
Absolute bioavailability
Measure the AUC(0-inf) of orally and intravenously (IV) administered Aramchol
Time frame: 10 days
Mass balance recovery
Assess the mass balance recovery of total amounts of radioactivity excreted in urine and feces
Time frame: 10 days
Metabolite profiling
Assess the potential metabolites of Aramchol and determine their chemical structure in plasma, urine and fecal samples
Time frame: 10 days
Routes and rates of elimination
Determine the routes and rates of elimination of \[14C\]-Aramchol in excreta
Time frame: 10 days
Chemical structure of each metabolite accounting for more than 10%
Identify the chemical structure of each metabolite accounting for more than 10% by area under the curve (AUC) of circulating total radioactivity or 10% of the dose in urine and feces
Time frame: 10 days
PK- Area under the concentration-time curve (AUC)
Investigate the plasma Area under the concentration-time curve (AUC) of Aramchol
Time frame: 10 days
PK- Time of maximum observed concentration (Tmax)
Investigate the plasma Time of maximum observed concentration (Tmax) of Aramchol
Time frame: 10 days
PK- Maximum observed concentration (Cmax)
Investigate the plasma Maximum observed concentration (Cmax) of Aramchol
Time frame: 10 days
PK- Total body clearance (CL)
Investigate the Total body clearance (CL) of Aramchol
Time frame: 10 days
Safety- Adverse events
Assess and characterize the number of participants with adverse events
Time frame: 10 days
Safety- Clinical laboratory parameters
Assess and characterize the number of participants with clinically significant changes in clinical laboratory parameters
Time frame: 10 days
Plan to share: No — Consideration will be made whether to share any data of this mass balance study
No publications or documents are linked to this record.
Ran from Jun 2020 to primary completion in Aug 2020, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aramchol
Galmed Pharmaceuticals Ltd